

PATIENT SUMMARY

European Association of Urology
Mr. E.N. van Kleffensstraat 5
6842 CV Arnhem
The Netherlands

Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma

Jens Bedke, Laurence Albiges, Umberto Capitanio, Rachel H. Giles, Milan Hora, Thomas B. Lam, Börje Ljungberg, Lorenzo Marconi, Tobias Klatte, Alessandro Volpe, Yasmin Abu-Ghanem, Saeed Dabestani, Sergio Fernández Pello, Fabian Hofmann, Teele Kuusk, Rana Tahbaz, Thomas Powles, Axel Bex

Eur Urol (2020), <https://doi.org/10.1016/j.eururo.2020.12.005>

This patient summary was written by Juul Seesing, editor EAU Communications Dept.

Patient summary was reviewed by Prof. Jens Bedke
EAU RCC Guidelines Panel member



Several trials in the field of advanced kidney cancer have been carried out of **immune checkpoint inhibitors**: a type of drugs that helps your immune system fight cancer. The data derived from these trials confirm that patients with advanced kidney cancer survive longer if they receive the following combination of:

- The drug axitinib as a tablet plus the liquid pembrolizumab injected into a vein
- The drug cabozantinib as a tablet plus the liquid nivolumab injected into a vein
- The liquids nivolumab and ipilimumab, both injected into a vein

As a result, the EAU Guidelines on kidney cancer recommend this combination as the first treatment for advanced kidney cancer.

Read the full article.